- BrainStorm Cell Therapeutics has signed a Letter of Intent with Minaris Advanced Therapies to manufacture NurOwn® for a Phase 3b clinical trial.
- The partnership strengthens BrainStorm’s U.S. manufacturing capabilities and supports its upcoming ALS trial.
BrainStorm Cell Therapeutics Inc. has entered a strategic collaboration with Minaris Advanced Therapies, signing a Letter of Intent to manufacture NurOwn® for its planned Phase 3b clinical trial. Minaris, a global CDMO with a focus on cell and gene therapies, will produce clinical trial material at its facility in Allendale, New Jersey.
The agreement initiates a technology transfer process for NurOwn®, an investigational stem cell therapy for amyotrophic lateral sclerosis (ALS). The collaboration aims to ensure readiness for BrainStorm’s multicentre clinical trial in the United States.
“We are excited to support BrainStorm in the next phase of NurOwn development,” said Eytan Abraham, Ph.D., Chief Commercial and Technology Officer at Minaris Advanced Therapies.
The partnership with Minaris complements BrainStorm’s recent collaboration with Pluri Inc. in Israel, forming part of a broader strategy to establish a robust, flexible manufacturing network. These efforts are intended to align clinical and manufacturing capabilities in preparation for both the trial and potential commercial production.
Chaim Lebovits, President and CEO of BrainStorm Cell Therapeutics, said the partnership “reflects our ongoing commitment to the ALS community and to advancing a therapy with the potential to meaningfully impact patients’ lives.”
